Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
The University of Sydney · Westmead Hospital · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
905
total citations
- FWCI
- 41.65
- Percentile
- 100%
- References
- 36
Citations per year
Authors
22- GVGeorgina V. LongCorresponding
The University of Sydney, Westmead Hospital, Melanoma Institute Australia, Westmead Institute
- UTUwe Trefzer
Charité - Universitätsmedizin Berlin
- MAMichael A. Davies
The University of Texas MD Anderson Cancer Center
- RKRichard Kefford
The University of Sydney, Westmead Hospital, Melanoma Institute Australia, Westmead Institute
- PAPaolo A. Ascierto
Fondazione IRCCS Istituto Nazionale dei Tumori
Topics & keywords
Topics
Keywords
- Dabrafenib
- Open label
- Metastatic melanoma
- Melanoma
- Medicine
- Oncology
- Mutant
- Internal medicine
No related works found for this paper.